CDKN1A and acute myeloid leukemia: This may not only be because ABBV-075 treatment alone reduces MCL1, BCL2, MYC, and CDK6 levels, but also because it increases p21, p27, and HEXIM1 levels in AML cells (Fig. 2e, f and S2D).